Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 38 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Linifanib in Treating Patients With Advanced, Refractory Colorectal CancerTerminatedNCT01365910Phase 2Results posted
• 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)TerminatedNCT01362348Phase 2Results posted
• Neoadjuvant Pazopanib in Renal Cell CarcinomaCompletedNCT01361113Phase 2Results posted
• ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerCompletedNCT01360554Phase 3Results posted
• A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or PlaceboCompletedNCT01359150Phase 2Results posted
• A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)CompletedNCT01357161Phase 2Results posted
• E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric CancerTerminatedNCT01355302Phase 1/2Results posted
• Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung CancerCompletedNCT01350817Phase 2Results posted
• Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT01349049Phase 1/2Results posted
• A Phase 2 Study of PLX3397 in Patients With Recurrent GlioblastomaTerminatedNCT01349036Phase 2Results posted
• Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
• Cabozantinib (XL184) in Men With Castrate-Resistant Prostate CancerCompletedNCT01347788Phase 1Results posted
• A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.CompletedNCT01346540Phase 1Results posted
• LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01345682Phase 3Results posted
• LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyTerminatedNCT01345669Phase 3Results posted
• A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR MutationsCompletedNCT01342965Phase 3Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or ParagangliomaTerminatedNCT01340794Phase 2Results posted
• Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsCompletedNCT01340651Phase 2Results posted
• Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade AstrocytomasTerminatedNCT01338857Phase 2Results posted
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients IICompletedNCT01335477Phase 3Results posted
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis PatientsCompletedNCT01335464Phase 3Results posted
• A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular CancerTerminatedNCT01334710Phase 2Results posted
• E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and NeckCompletedNCT01332266Phase 1/2Results posted
• Bosutinib in Adult Patients With Recurrent GlioblastomaCompletedNCT01331291Phase 2Results posted
• Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic ChondrosarcomaCompletedNCT01330966Phase 2Results posted
• A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc IntervalCompletedNCT01328054Phase 4Results posted
• Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT01325701Phase 2Results posted
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)CompletedNCT01321554Phase 3Results posted
• Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant MelanomaCompletedNCT01321437Phase 2Results posted
• Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)CompletedNCT01317875Phase 1Results posted
• A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) PopulationTerminatedNCT01313663Phase 2Results posted
• Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedNCT01310855Phase 2Results posted
• A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) MutationsCompletedNCT01310036Phase 2Results posted
• Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT01309997Phase 2Results posted
• A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01309737Phase 3Results posted
• Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC PatientsCompletedNCT01306942Phase 1/2Results posted
• Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedNCT01306045Phase 2Results posted
• Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT01302808Phase 1Results posted
• Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of ChemotherapyTerminatedNCT01301391Phase 2Results posted
• Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human SubjectsCompletedNCT01299285Phase 1Results posted
• Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal CancerCompletedNCT01298570Phase 2Results posted
• Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of AfatinibCompletedNCT01298063Phase 1Results posted
• Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated CapsuleCompletedNCT01297595Phase 1Results posted
• A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell CarcinomaCompletedNCT01297244Phase 2Results posted
• MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyCompletedNCT01294306Phase 2Results posted
• Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01292135Phase 1Results posted
• First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With RegorafenibCompletedNCT01289821Phase 2Results posted
• Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.CompletedNCT01289028Phase 3Results posted
• A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR MutationsCompletedNCT01287754Phase 4Results posted
• A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma KinaseCompletedNCT01283516Phase 1Results posted
• Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue SarcomaCompletedNCT01281865Phase 1/2Results posted
• Pazopanib as Single Agent in Advanced NETsCompletedNCT01280201Phase 2Results posted
• A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01276639Phase 3Results posted
• Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01275586Early Phase 1Results posted
• Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP PatientsCompletedNCT01275196Phase 3Results posted
• Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT01274351Phase 2Results posted
• Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT01273610Phase 2Results posted
• A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast CancerTerminatedNCT01272141Phase 2Results posted
• LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment FailuresCompletedNCT01271725Phase 2Results posted
• Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)CompletedNCT01271712Phase 3Results posted
• E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular CarcinomaCompletedNCT01271504Phase 1/2Results posted
• A Study of E7080 in Subjects With Solid TumorCompletedNCT01268293Phase 1Results posted
• Saracatinib in Treating Patients With Prostate CancerTerminatedNCT01267266Phase 2Results posted
• Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT01267253Phase 2Results posted
• TKI 258 in Von Hippel-Lindau Syndrome (VHL)TerminatedNCT01266070Phase 2Results posted
• Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA MethylationCompletedNCT01265953Not applicableResults posted
• Study of Bavituximab and Sorafenib In Patients With Advanced Liver CancerCompletedNCT01264705Phase 1/2Results posted
• Lapatinib in Stage IV Melanoma With ERBB4 MutationsTerminatedNCT01264081Phase 2Results posted
• Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)CompletedNCT01263769Phase 2Results posted
• Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing BevacizumabCompletedNCT01262820Phase 2Results posted
• Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid ArthritisCompletedNCT01262118Phase 1Results posted
• TKI258 for Metastatic Inflammatory Breast Cancer PatientsCompletedNCT01262027Phase 2Results posted
• Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With DocetaxelCompletedNCT01260688Phase 2Results posted
• A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsCompletedNCT01260181Phase 2Results posted
• Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerCompletedNCT01259089Phase 1/2Results posted
• A Phase 1b Trial in Patients With Renal Cell CancerCompletedNCT01258348Phase 1Results posted
• Treatment of Corneal Neovascularization With Topical PazopanibCompletedNCT01257750Phase 1/2Results posted
• Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01256398Phase 2Results posted
• Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical CancerCompletedNCT01255137Phase 2Results posted
• Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic SyndromeCompletedNCT01254890Phase 1/2Results posted
• Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesCompletedNCT01254864Phase 2Results posted
• Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia PatientsCompletedNCT01254188Phase 3Results posted
• Brivanib Metastatic Renal Cell CarcinomaTerminatedNCT01253668Phase 2Results posted
• Pazopanib in Patients With Relapsed or Refractory Small Cell Lung CancerCompletedNCT01253369Phase 2Results posted
• Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01253070Phase 2Results posted
• Phase l/II Study of Ruxolitinib for Acute LeukemiaTerminatedNCT01251965Phase 1/2Results posted
• A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066CompletedNCT01250730Phase 1Results posted
• A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.CompletedNCT01250119Phase 2Results posted
• BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01248247Phase 2Results posted
• Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205TerminatedNCT01247922Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT01247571Phase 2Results posted
• A Study of LY3009104(Baricitinib) for Healthy SubjectsCompletedNCT01247350Phase 1Results posted
• CP-690-550 Ointment For Chronic Plaque PsoriasisCompletedNCT01246583Phase 2Results posted
• Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerTerminatedNCT01244191Phase 3Results posted
• Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)CompletedNCT01243944Phase 3Results posted
• Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)TerminatedNCT01242514Phase 3Results posted
• A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01241591Phase 3Results posted
• Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01238211Phase 2Results posted
• Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid CancerCompletedNCT01236547Phase 2Results posted
• Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01236391Phase 2Results posted

← Tyrosine Kinase Inhibitors overview